Change over period: —
NSE · KOPRAN
KOPRAN LTD.
-8.6% from the 52-week high · +146.1% above the low
Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. The company is headquartered in Mumbai, Maharashtra. The firm is engaged in the business of manufacturing and supplying international formulations (Finished Dosage Form) and active pharmaceutical ingredients (APIs). Its formulation business unit manufactures oral solid dosages and dry powder formulations for both penicillin and non-penicillin-based drugs. Its APIs business unit offers Sterile Cephalosporins and Carbapenems. The company also offers Macrolide, Antibacterial, Anticonvulsant, and Cardiovascular range of drugs. Its product offering includes antibiotics, cardiovascular, antidiabetic, gastrointestinal, pain management, drugs for erectile dysfunction, antiallergics, respiratory, oncology, central nervous system, antiprotozoal, and anthelmintics. Its antibiotics brands include AMPIK 250 / 500, AMPIK SYRUP, and AMYN - 250 / 500. Its cardiovascular brands include CARDIOTEN - 25 / 50 / 100, CADITONE - 3.125 / 6.25 / 12.5 / 25 and KLODIP - 5 / 10.
The short version. KOPRAN LTD. reported revenue of ₹211 crore for Sep 2026, up 78.8% from a year earlier. Net profit was ₹4 crore. Return on equity was 4.9% in Mar 2026. Promoter holding was 41.82% in Sep 2026, down 2.64 points over 8 quarters.
1 · The price
How has the stock traded?
KOPRAN LTD. trades 8.6% below its 52-week high and 146.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹211 cr.
10.5 pts higher than a year earlier.
Revenue compounded at 7.2% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 211 | 154 | 234 | 194 | 118 | 135 | 172 | 166 |
| Net profit | 4 | 7 | 19 | 9 | -10 | 7 | 10 | 10 |
| Net margin % | 2.1 | 4.4 | 8.1 | 4.8 | -8.4 | 5.5 | 5.6 | 6.3 |
| EPS (₹) | 0.91 | 1.39 | 3.91 | 1.93 | -2.06 | 1.54 | 2.0 | 2.15 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 681 | 630 | 615 | 551 | 478 | 492 | 359 | 358 |
| Net profit | 26 | 39 | 51 | 27 | 61 | 62 | 21 | 24 |
| Net margin % | 3.8 | 6.1 | 8.3 | 4.9 | 12.8 | 12.5 | 5.8 | 6.7 |
| EPS (₹) | 5.33 | 7.98 | 10.57 | 5.65 | 12.66 | 14.24 | 4.86 | 5.55 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 4.9% in Mar 2026; debt to equity is 0.29.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 4.9 | 7.4 | 10.4 | 6.2 |
| Return on capital % | 8.0 | 10.4 | 14.5 | 8.9 |
| EBITDA margin % | 9.1 | 12.1 | 14.1 | 9.9 |
| Net margin % | 3.8 | 6.1 | 8.1 | 4.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 7.2% | 6.0% |
| Profit CAGR | -1.9% | -16.0% |
4 · The owners
Who holds it, and are they adding?
Down 2.64 pts over 8 quarters.
Up 0.05 pts over 8 quarters.
+0 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 44.46 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 44.42 | 41.82 | -2.64 |
| FII | 0.86 | 1.12 | 0.76 | 0.6 | 0.36 | 0.57 | 0.51 | 0.91 | +0.05 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 54.68 | 54.45 | 54.82 | 54.98 | 55.22 | 55.0 | 55.06 | 57.27 | +2.59 |
Mutual fund holdings · Oct 2026
2 schemes hold this stock
2 the month before.
- Motilal Oswal BSE Healthcare ETF0.04% of NAV
- Bandhan BSE Healthcare Index Fund0.04% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for KOPRAN LTD. are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about KOPRAN LTD.
What is the KOPRAN LTD. share price?
KOPRAN LTD. (KOPRAN) last closed at ₹266.74, up 0.3% on the day. Its 52-week range is ₹108.04 to ₹290.90.
What is the market cap of KOPRAN LTD.?
KOPRAN LTD. has a market capitalisation of about ₹1,282 crore. Its price-to-earnings ratio is 32.4.
How are KOPRAN LTD.'s latest results?
KOPRAN LTD. reported revenue of ₹211 crore for Sep 2026, up 78.8% from a year earlier. Net profit was ₹4 crore. Return on equity was 4.9% in Mar 2026. Promoter holding was 41.82% in Sep 2026, down 2.64 points over 8 quarters.
Who owns KOPRAN LTD.?
As of Sep 2026, shareholding was: Promoter 41.82%, FII 0.91%, Public 57.27%.
How many mutual funds hold KOPRAN LTD.?
2 mutual fund schemes held KOPRAN LTD. in October 2026. That compares with 2 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 04 Sep 2025 · Final Dividend - Rs. 3
- 02 Sep 2024 · Final Dividend - Rs. 3
- 07 Sep 2023 · Dividend - Rs. 3
- 04 Aug 2022 · Final Dividend - Rs. 3
- 05 Aug 2021 · Final Dividend - Rs. 1.5
- 05 Nov 2020 · Interim Dividend - Rs. 1.5
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.